Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
about
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.Ruxolitinib-associated infections: A systematic review and meta-analysis.
P2860
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@ast
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@en
type
label
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@ast
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@en
prefLabel
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@ast
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@en
P2093
P2860
P50
P1433
P1476
Ruxolitinib in clinical practi ...... po Laziale of Ph-negative MPN.
@en
P2093
Alessandro Andriani
Ambra Di Veroli
Antonietta Centra
Antonio Spadea
Barbara Anaclerico
Francesca Celesti
Francesco Buccisano
Fulvio Massaro
Gioia Colafigli
Giuseppe Cimino
P2860
P304
P356
10.1007/S00277-016-2884-7
P577
2016-11-26T00:00:00Z